In vitro effects of selective serotonin reuptake inhibitors on Cryptococcus gattii capsule and biofilm.

IF 2.7 4区医学 Q3 IMMUNOLOGY

Pathogens and disease Pub Date : 2024-02-07 DOI:10.1093/femspd/ftae001

Letícia Rampazzo da Gama Viveiro, Amanda Rodrigues Rehem, Evelyn Luzia De Souza Santos, Paulo Henrique Fonseca do Carmo, Juliana Campos Junqueira, Liliana Scorzoni

{"title":"In vitro effects of selective serotonin reuptake inhibitors on Cryptococcus gattii capsule and biofilm.","authors":"Letícia Rampazzo da Gama Viveiro, Amanda Rodrigues Rehem, Evelyn Luzia De Souza Santos, Paulo Henrique Fonseca do Carmo, Juliana Campos Junqueira, Liliana Scorzoni","doi":"10.1093/femspd/ftae001","DOIUrl":null,"url":null,"abstract":"<p><p>Infections caused by Cryptococcus gattii mainly affect immunocompetent individuals and the treatment presents important limitations. This study aimed to validate the efficacy of selective serotonin reuptake inhibitors (SSRI), fluoxetine hydrochloride (FLH), and paroxetine hydrochloride (PAH) in vitro against C. gattii. The antifungal activity of SSRI using the microdilution method revealed a minimal inhibitory concentration (MIC) of 31.25 µg/ml. The combination of FLH or PAH with amphotericin B (AmB) was analyzed using the checkerboard assay and the synergistic effect of SSRI in combination with AmB was able to reduce the SSRI or AmB MIC values 4-8-fold. When examining the effect of SSRI on the induced capsules, we observed that FLH and PAH significantly decreased the size of C. gattii capsules. In addition, the effects of FLH and PAH were evaluated in biofilm biomass and viability. The SSRI were able to reduce biofilm biomass and biofilm viability. In conclusion, our results indicate the use of FLH and PAH exhibited in vitro anticryptococcal activity, representing a possible future alternative for the cryptococcosis treatment.</p>","PeriodicalId":19795,"journal":{"name":"Pathogens and disease","volume":" ","pages":""},"PeriodicalIF":2.7000,"publicationDate":"2024-02-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10849314/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pathogens and disease","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1093/femspd/ftae001","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"IMMUNOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Infections caused by Cryptococcus gattii mainly affect immunocompetent individuals and the treatment presents important limitations. This study aimed to validate the efficacy of selective serotonin reuptake inhibitors (SSRI), fluoxetine hydrochloride (FLH), and paroxetine hydrochloride (PAH) in vitro against C. gattii. The antifungal activity of SSRI using the microdilution method revealed a minimal inhibitory concentration (MIC) of 31.25 µg/ml. The combination of FLH or PAH with amphotericin B (AmB) was analyzed using the checkerboard assay and the synergistic effect of SSRI in combination with AmB was able to reduce the SSRI or AmB MIC values 4-8-fold. When examining the effect of SSRI on the induced capsules, we observed that FLH and PAH significantly decreased the size of C. gattii capsules. In addition, the effects of FLH and PAH were evaluated in biofilm biomass and viability. The SSRI were able to reduce biofilm biomass and biofilm viability. In conclusion, our results indicate the use of FLH and PAH exhibited in vitro anticryptococcal activity, representing a possible future alternative for the cryptococcosis treatment.

查看原文本刊更多论文

选择性 5-羟色胺再摄取抑制剂对隐球菌胶囊和生物膜的体外影响

由加特隐球菌引起的感染主要影响免疫力低下的人，治疗方法存在很大的局限性。本研究旨在验证选择性羟色胺再摄取抑制剂（SSRI）盐酸氟西汀（FLH）和盐酸帕罗西汀（PAH）对加特纳隐球菌的体外疗效。采用微量稀释法检测 SSRI 的抗真菌活性，发现其最小抑制浓度（MIC）为 31.25 μg/mL。使用棋盘试验分析了 FLH 或 PAH 与 AmB 的组合，SSRI 与 AmB 组合的协同效应可将 SSRI 或 AmB 的 MIC 值降低 4 至 8 倍。在研究 SSRI 对诱导蒴果的影响时，我们观察到 FLH 和 PAH 能显著缩小 C. gattii 的蒴果。此外，我们还评估了 FLH 和 PAH 对生物膜生物量和活力的影响。SSRI 能够降低生物膜生物量和生物膜活力。总之，我们的研究结果表明，FLH 和 PAH 具有体外抗隐球菌活性，是未来治疗隐球菌病的一种可能选择。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Pathogens and disease IMMUNOLOGY-INFECTIOUS DISEASES

CiteScore

7.40

自引率

3.00%

发文量

期刊介绍： Pathogens and Disease publishes outstanding primary research on hypothesis- and discovery-driven studies on pathogens, host-pathogen interactions, host response to infection and their molecular and cellular correlates. It covers all pathogens – eukaryotes, prokaryotes, and viruses – and includes zoonotic pathogens and experimental translational applications.